Thermo Fisher Scientific (TMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2014 | 09-2014 | 06-2014 | 03-2014 | 12-2013 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,343,500 | 534,300 | 584,900 | 1,497,200 | 5,826,000 |
| Marketable Securities | N/A | 9,300 | 21,000 | 25,500 | 4,500 |
| Receivables | 2,473,600 | 2,507,100 | 2,660,100 | 2,695,500 | 1,942,300 |
| Inventories | 1,859,500 | 1,913,700 | 1,933,800 | 2,060,500 | 1,494,500 |
| Income taxes - deferred | 303,300 | 230,600 | 237,500 | 230,100 | 192,500 |
| Other current assets | 559,900 | 524,900 | 507,100 | 797,300 | 420,900 |
| TOTAL | $6,539,800 | $5,719,900 | $5,944,400 | $7,306,100 | $9,880,700 |
| Non-Current Assets | |||||
| PPE Net | 2,426,500 | 2,406,100 | 2,472,000 | 2,488,700 | 1,767,400 |
| Intangibles | 32,952,700 | 33,745,100 | 35,060,900 | 35,505,900 | 19,574,600 |
| Other Non-Current Assets | 933,100 | 819,700 | 836,100 | 833,000 | 640,700 |
| TOTAL | $36,312,300 | $36,970,900 | $38,369,000 | $38,827,600 | $21,982,700 |
| Total Assets | $42,852,100 | $42,690,800 | $44,313,400 | $46,133,700 | $31,863,400 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 820,700 | 818,100 | 849,900 | 828,800 | 691,500 |
| Accrued Expenses | 668,900 | 627,800 | 535,800 | 518,500 | 432,000 |
| TOTAL | $5,349,800 | $6,222,100 | $6,235,600 | $5,391,500 | $3,126,000 |
| Non-Current Liabilities | |||||
| Long Term Debt | 12,351,600 | 11,388,600 | 12,502,000 | 15,196,900 | 9,499,600 |
| Deferred Revenues | 311,900 | 325,900 | 342,500 | 336,600 | 198,900 |
| Other Non-Current Liabilities | 1,171,900 | 1,096,400 | 1,128,900 | 1,129,100 | 771,800 |
| TOTAL | $16,954,200 | $15,958,100 | $17,419,200 | $20,311,600 | $11,881,300 |
| Total Liabilities | $22,304,000 | $22,180,200 | $23,654,800 | $25,703,100 | $15,007,300 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 396,783 | 400,026 | 399,355 | 398,938 | 391,792 |
| Common Shares | 408,500 | 408,000 | 407,200 | 406,800 | 369,600 |
| Retained earnings | 10,406,900 | 9,866,000 | 9,454,600 | 9,236,300 | 8,753,300 |
| Other shareholders' equity | -1,284,900 | -724,700 | -111,800 | -62,400 | -77,400 |
| TOTAL | $20,548,100 | $20,510,600 | $20,658,600 | $20,430,600 | $16,856,100 |
| Total Liabilities And Equity | $42,852,100 | $42,690,800 | $44,313,400 | $46,133,700 | $31,863,400 |